ProKidney Stock (NASDAQ:PROK)
Previous Close
$1.53
52W Range
$1.18 - $4.44
50D Avg
$1.84
200D Avg
$2.21
Market Cap
$425.90M
Avg Vol (3M)
$614.85K
Beta
1.30
Div Yield
-
PROK Company Profile
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVMD | Revolution Medicines, Inc. |
| MRUS | Merus N.V. |
| STOK | Stoke Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| REPL | Replimune Group, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| ARVN | Arvinas, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| IMCR | Immunocore Holdings plc |
| GLUE | Monte Rosa Therapeutics, Inc. |
| PCVX | Vaxcyte, Inc. |
| THRD | Third Harmonic Bio, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| ACLX | Arcellx, Inc. |
| KURA | Kura Oncology, Inc. |